Post‐transcriptional control of expression of sFlt‐1, an endogenous inhibitor of vascular endothelial growth factor
- 17 June 2004
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 93 (1) , 120-132
- https://doi.org/10.1002/jcb.20142
Abstract
Vascular endothelial growth factor (VEGF) is a major modulator of angiogenesis. Biological effects of VEGF are mediated by endothelial cell-surface receptors, KDR and Flt-1. Alternative Flt-1 RNA processing, involving retention of intron 13 and the use of intronic cleavage-polyadenylation signals, produces a secreted form of Flt-1, “sFlt-1,” that binds VEGF with high affinity and can inhibit VEGF signaling. To probe mechanisms controlling sFlt-1 expression, we have cloned and sequenced Flt-1 intron 13 from a mouse genomic library and located RNA processing signals potentially involved in sFlt-1 mRNA formation. A minigene construct containing Flt-1 intron 13 directed the expression of both secreted (i.e., cleaved/polyadenylated) and transmembrane (i.e., spliced) forms of Flt-1 mRNA and protein. Using rapid amplification of 3′ cDNA ends (3′-RACE) and quantitative PCR (QPCR) analysis to test the activity of intronic cleavage-polyadenylation signals, we observed that multiple sites were utilized for sFlt-1 mRNA processing in both native tissues and Flt-1 minigene transfectants. In transfectants, the most distal signal was utilized preferentially. The potential for interaction between pathways leading to sFlt-1 or full-length Flt-1 was evaluated using QPCR to measure relevant mRNAs after transfection with signal mutants. Decreased expression of sFlt-1 mRNA in cleavage-polyadenylation mutants was accompanied by reciprocal increases in full-length Flt-1 mRNA. Multiple sFlt-1 mRNA species are formed that differ by up to 3.9 kb in their 3′-untranslated regions (UTRs), which contain sites of potential regulatory importance. The reciprocity between sFlt-1 and Flt-1 mRNA expression suggests a novel post-transcriptional mechanism by which sFlt-1 protein production and, thereby, responsiveness to VEGF, may be modulated.Keywords
This publication has 37 references indexed in Scilit:
- Down‐regulation of Flt‐1 gene expression by the proteasome inhibitor MG262Journal of Cellular Biochemistry, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Angiogenesis-dependent diseasesSeminars in Oncology, 2001
- The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancerSeminars in Oncology, 2001
- Regional Suppression of Tumor Growth byIn VivoTransfer of a cDNA Encoding a Secreted Form of the Extracellular Domain of theflt-1Vascular Endothelial Growth Factor ReceptorHuman Gene Therapy, 1998
- Receptor tyrosine kinases as targets for inhibition of angiogenesisDrug Discovery Today, 1997
- Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDRBiochemical and Biophysical Research Communications, 1996
- Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.Genome Research, 1995
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences, 1993
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993